Liver Transplant; Complications Clinical Trial
Official title:
A Randomized, Controlled, Open-label, Multi-center Clinical Trial of Multi-kinase Inhibitor Combined With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma and High-risk Recurrence Factors After Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety in liver transplant recipients at high risk of recurrence in hepatocellular carcinoma. 2. The primary objective of this study is to evaluate the efficacy of multi-kinase inhibitors in combination with bevacizumab as adjuvant therapy in liver transplant recipients with hepatocellular carcinoma who present high-risk factors for recurrence, based on the one-year recurrence-free survival rate (1-year RFS rate). 3. The secondary objectives of this study are to assess the effectiveness and safety of multi-kinase inhibitors in combination with bevacizumab as adjuvant therapy in liver transplant recipients with hepatocellular carcinoma who present high-risk factors for recurrence, based on the following parameters: Recurrence-free survival (RFS) duration, Overall survival (OS), Two-year and three-year RFS rates, Graft survival, Quality of life evaluation (QoL), Incidence of adverse events and serious adverse events.
To investigate the effect of multikinase inhibitors (including sorafenib, lenvatinib and donafinib) combined with bevacizumab on recurrence, survival and safety in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after liver transplantation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05818644 -
Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
|
||
Recruiting |
NCT04443322 -
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
|
N/A | |
Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
Completed |
NCT03165916 -
Study to Compare the Incidence of Biliary Complications After Liver Transplantation
|
N/A | |
Withdrawn |
NCT04216303 -
Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
|
||
Recruiting |
NCT04506398 -
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
|
||
Not yet recruiting |
NCT05853484 -
Home-based Bimodal Lifestyle Intervention in Patients With Liver Cirrhosis Awaiting Orthotopic Liver Transplantation
|
N/A | |
Not yet recruiting |
NCT05036031 -
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
|
||
Recruiting |
NCT05065125 -
Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlass™) for Post-liver Transplant Anastomotic Stricture
|
||
Recruiting |
NCT06060392 -
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
|
N/A | |
Enrolling by invitation |
NCT05195944 -
Semaglutide vs Sitagliptin
|
Phase 4 | |
Completed |
NCT05255510 -
Risk of Acute Kidney Injury in Living Liver Donor Surgery
|
||
Not yet recruiting |
NCT06048445 -
Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children
|
||
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Completed |
NCT04182256 -
Magnetic Spiderman for Preparation of Liver Donation
|
N/A | |
Recruiting |
NCT04327427 -
Outcome Analysis of Aspirin in Liver Transplantation
|
||
Recruiting |
NCT04477967 -
Design and Implementation of the Pediatric Liver Transplantation Biobank
|
||
Recruiting |
NCT05109156 -
Preoperative Sepsis Timeline, Profile and Its Association With Recipient Outcome Following Live Donor Liver Transplant
|
||
Recruiting |
NCT06124209 -
Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial
|
Phase 4 | |
Recruiting |
NCT04054999 -
Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
|
Phase 4 |